


We claim:

1. A compound having the structure of Formula I



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,

- 5 diastereomers, polymorphs or N-oxides

wherein

m is an integer from 0-2;

R₁ can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclalkyl;

- 10 **R₂** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl, or heterocyclalkyl;

R₁ and **R₂** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino,

- 15 cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F, Cl, Br, I), aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl or heterocyclalkyl;

R₃ can be NH₂, NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or OR_m (wherein R_m can be hydrogen, alkyl, aralkyl, aryl, or metal ions (Na⁺, K⁺, Li⁺, Ca⁺ or Mg⁺));

- 20 **R₄** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl, heterocyclalkyl, -(CH₂)₁₋₄-O-R' (wherein R' can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclalkyl, or heteroarylalkyl), -C(=O)-R₃ (wherein R₃ is the same as defined above) -C(=O)R_z (wherein R_z is -NR₇R₈ wherein R₇ and R₈ can be independently selected

from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclalkyl); or R_7 and R_8 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl; or

10 $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or $-N(CN)$ and R_u is the same as defined above) or -

15 $C(=O)OR_u$ (wherein R_u is the same as defined above)];

R_5 and R_6 may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or R_5 and R_6 may together join to form a cycloalkyl ring.

2. A compound according to claim 1, wherein R_1 is hydrogen or alkyl.
- 20 3. A compound according to claim 1, wherein R_1 is hydrogen.
4. A compound of claim 1, wherein R_1 is alkyl.
5. A compound according to claim 1, wherein R_1 is methyl.
6. A compound according to claim 1, wherein R_2 is hydrogen, aralkyl, heteroarylalkyl or aryl.
- 25 7. A compound according to claim 1, wherein R_2 is hydrogen.
8. A compound according to claim 1, wherein R_2 is optionally substituted aralkyl.
9. A compound according to claim 8, wherein the optional substituents on aralkyl are halo, hydroxy, alkynyloxy, aryl, $-NHC(=O)R_9$, $-OC(=O)R_9$ or $-OCH_2R_9$.

10. A compound according to claim 10, wherein the optional substituent on aralkyl is -NHC(=O)R₉ wherein R₉ is optionally substituted group selected from heteroaryl, heterocyclyl or aryl.
11. A compound according to claim 10, wherein R₉ is pyridyl, morpholinyl, 5 methylpiperazinyl, bromopyridyl, phenyl, piperidinyl, difluorophenyl, dichlorophenyl, dichloropyridyl or methoxyphenyl.
12. A compound according to claim 9, wherein the optional substituent on aralkyl is -OC(=O)R₉ wherein R₉ is optionally substituted group selected from heterocyclyl.
13. A compound according to claim 12, wherein R₉ is morpholinyl, methylpiperazinyl.
- 10 14. A compound according to claim 9, wherein the optional substituent on aralkyl is -OCH₂R₉ wherein R₉ is optionally substituted group is selected from aryl, heterocyclyl and alkynyl.
15. A compound according to claim 14, wherein R₉ is difluorophenyl, chlorophenyl, dichlorophenyl, piperidinyl, morpholinyl, methylpiperazinyl or propargyl.
- 15 16. A compound according to claim 1, wherein R₂ is heteroarylalkyl.
17. A compound according to claim 16, wherein R₂ is indolylmethyl.
18. A compound according to claim 1, wherein R₂ is aryl.
19. A compound according to claim 18, wherein R₂ is phenyl or benzodioxolyl.
20. A compound according to claim 1, wherein R₁ and R₂ may also together join to 20 form cyclic ring (3-8 membered), optionally benzofused containing 0-4 heteroatoms O, S or N.
21. A compound according to claim 20, wherein R₁ and R₂ together joins to form tetrahydroisoquinoline ring.
22. A compound according to claim 1, wherein R₃ is -OR_m or -NH₂.

23. A compound according to claim 22, wherein R_3 is $-OR_m$.
24. A compound according to claim 23, wherein R_m is hydrogen, aralkyl or alkyl,
25. A compound according to claim 24, wherein R_m is hydrogen.
26. A compound according to claim 23, wherein R_m is alkyl or aralkyl.
- 5 27. A compound according to claim 26, wherein R_m is methyl, ethyl, butyl or tert-butyl.
28. A compound according to claim 22, wherein R_3 is $-NH_2$.
29. A compound according to claim 1, wherein R_4 is $-C(=O)R_z$, optionally substituted alkyl or $-C(=O)R_3$.
- 10 30. A compound according to claim 29, wherein R_4 is $-C(=O)R_z$.
31. A compound according to claim 30, wherein R_z is $-NR_7R_8$.
32. A compound according to claim 31, wherein R_7 is hydrogen, optionally substituted alkyl or heteroarylalkyl.
33. A compound according to claim 32, wherein R_7 is hydrogen.
- 15 34. A compound according to claim 32, wherein R_7 is optionally substituted alkyl.
35. A compound of claim 34, wherein R_7 is hydroxymethyl or methyl.
36. A compound of claim 32, wherein R_7 is heteroarylalkyl.
37. A compound of claim 36, wherein R_7 is thiophenylmethyl.
38. A compound according to claim 31, wherein R_8 is hydrogen or optionally substituted groups selected from aryl, aralkyl, heteroarylalkyl, cycloalkyl, alkyl, heterocyclalkyl, heterocycl, heteroaryl, alkenyl, alkynyl and alkoxy.
- 20 39. A compound of claim 38, wherein R_8 is hydrogen.
40. A compound of claim 38, wherein R_8 is optionally substituted aryl or aralkyl.

41. A compound of claim 40, wherein R₈ is chlorophenyl, dichlorophenyl, methoxyphenyl biphenyl, methylphenyl, fluorophenyl, diethylphenyl, isopropylphenyl, difluorophenyl, trifluoromethylphenyl, ethylphenyl, cyclopentyloxyphenyl, methoxybenzyl, dihydroindolyl, indolyl or benzodioxolyl.

5 42. A compound of claim 38, wherein R₈ is heteroarylalkyl or heteroaryl.

43. A compound of claim 42, wherein R₈ is thiophenylmethyl, thiazolyl, benzothiazolyl, pyridyl, thiadiazolylmethyl, indolylethyl, thiophenylethyl, pyridylmethyl, indolylethyl, methylthiadiazolyl, benzyl-tert-butyl-pyrazolyl, tolyl-tert-butyl-pyrazolyl, ethylsulphenylthiadiazolyl, dimethylthiazolyl or thiazolyl.

10 44. A compound of claim 38, wherein R₈ is optionally substituted heterocyclyl.

45. A compound of claim 44, wherein R₈ is methylpiperazinyl, methylpiperidinyl, piperidinyl or morpholinyl.

46. A compound of claim 38, wherein R₈ is optionally substituted cycloalkyl.

47. A compound of claim 46, wherein R₈ is cyclopropyl, cyclohexyl, adamantyl, cyclopentyl, hydroxycyclohexyl or cycloheptyl.

48. A compound of claim 38, wherein R₈ is optionally substituted alkyl, alkenyl or alkynyl.

49. A compound of claim 48, wherein R₈ is isopropyl, isobutyl, isopentyl, propenyl, propynyl, hydroxymethyl, hexyl or butyl.

20 50. A compound of claim 38, wherein R₈ is optionally substituted alkoxy.

51. A compound of claim 50, wherein R₈ is benzyloxy or methoxy.

52. A compound of claim 31, wherein R₇ and R₈ together joins to form an optionally substituted heterocyclic ring system.

53. A compound of claim 52, wherein R₇ and R₈ together joins to form 25 methylpiperazinyl, benzyloxycarbonyl pyrrolidinyl, carboxypyrrolidinyl, dihydroindolyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, oxo-piperidinyl or piperazinyl.

54. A compound of claim 29, wherein R₄ is optionally substituted alkyl selected from methyl.
55. A compound of claim 29, wherein R₄ is -(CH₂)₁₋₄OR'.
56. A compound of claim 55, wherein R₄ is hydroxymethyl, methoxymethyl or benzyloxymethyl.
57. A compound of claim 29, wherein R₄ is -(CH₂)₁₋₄NR_xR_y.
58. A compound of claim 57, wherein R₄ is methylenepyrrolidinyl.
59. A compound of claim 1, wherein R₄ is -C(=O)R₃.
60. A compound of claim 59, wherein R₃ is -OR_m.
- 10 61. A compound of claim 60, wherein R_m is hydrogen or alkyl.
62. A compound of claim 61, wherein R_m is hydrogen.
63. A compound of claim 61, wherein R_m is alkyl.
64. A compound of claim 63, wherein R_m is ethyl.
65. A compound of claim 1, wherein R₅ is hydrogen, alkyl or aryl.
- 15 66. A compound of claim 65, wherein R₅ is hydrogen.
67. A compound of claim 65, wherein R₅ is alkyl.
68. A compound of claim 67, wherein R₅ is methyl.
69. A compound of claim 65, wherein R₅ is aryl.
70. A compound of claim 69, wherein R₅ is phenyl.
- 20 71. A compound of claim 1, wherein R₆ is hydrogen.
72. A compound of claim 1, wherein R₆ is alkyl.
73. A compound of claim 72, wherein R₆ is methyl.

74. A compound of claim 1, wherein R₆ is aryl.
75. A compound of claim 74, wherein R₆ is phenyl.
76. A compound of claim 1, wherein m is 0 or 1.
77. A compound selected from

- 5 (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionic acid (Compound No. 1),
(S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 2),
- 10 (S)-3-(4-Benzoylamino-phenyl)-2-{{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 3),
(S)-3-(4-Hydroxy-phenyl)-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 4),
(S)-2-{{[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 5),
- 15 (S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound no. 6),
(S)-3-(4-Benzoylamino-phenyl)-2-{{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7),
- 20 (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8),
(S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.10),
- 25 Lithium salt of (S)-2-{{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No.11),
Lithium salt of (S)-2-{{[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No. 12),
- 30 Lithium salt of (S)-2-{{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionate (Compound No. 13),

- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14),
- Morpholine-4-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15),
- 5 4-Methyl-piperazine-1-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenylester (Compound No. 16),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 17),
- 10 (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 18),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(piperidine-4-carbonyl)-amino]-phenyl]-propionic-acid, salt with trifluoroacetic acid (Compound No.19),
- 15 (S)-2-{[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 20),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-2-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 21),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[6-bromo-pyridine-2-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 22),
- 20 (S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 23),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxyl-phenyl)-propionic acid (Compound No. 24),
- 25 (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-prop-2-ynyl-phenyl)-propionic-acid (Compound No. 27),
- 30 (S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 28),
- (S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-methoxy-benzyl-amino)-phenyl]-propionic acid (Compound No 29),
- 35 (S)-2-{[(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic-acid (Compound No. 30),

- (S)-3-(4-(2,6-Dichlorobenzyl)-phenyl]-2-[{(4R,5R)-5-[thiophen-2-yl-methyl]-carbamoyl}-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 31),
- (S)-3-[4-(2,6-Dichloro-benzyl)-phenyl]-2-{{(4R,5R)-5-phenyl-carbamoyl}-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (compound no 32),
- 5 (S)-2-{{(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridin-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No 33),
- (S)-2-{{(4S,5S)-5-(Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichlorobenzloxy-phenyl]-propionic acid (Compound No.34),
- 10 (4R,5R)-5-{{(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyl)-phenyl]-ethyl-carbamoyl}-[1,3]dioxolane-4-carboxylic acid (Compound No. 35),
- Lithium salt of (S)-2-{{(4R,5R)-5-Cyclopropyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichlorobenzyl)-phenyl]-propionate (Compound No. 36),
- (S)-2-{{(4R,5R)-5-Cyclohexane-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyl)-phenyl]-propionic acid (Compound No 37) ,
- 15 (S)-3-[4-(2,6-Dichlorobenzyl)-phenyl]-2-{{(4R,5R)-5-(thiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 38) ,
- (S)-2-{{(4R,5R)-5-(Cyclopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-{{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No 39) ,
- 20 (S)-2-{{(4R,5R)-5-Cyclohexyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino}-3-{{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 40),
- (S)-2-{{(4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbamoyl]-amino}-3-{{4-[(pyridine-4-carbonyl-amino]-phenyl}-propionic acid (Compound No. 41) ,
- (4R,5R)-5-[(S)-1-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 42) ,
- 25 (S)-3-(4-benzoylaminophenyl)-2-{{(4R,5R)-5-(isopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 43),
- (S)-3-[4-(2,6-Dichloro-benzyl)-phenyl]-2-{{(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid salt with trifluoroacetic acid (Compound No 44),
- 30 (S)-2-{{(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 45),
- (4R,5R)-5-{{(S)-Carboxy-2-[4-(2,6-dichlorobenzyl)-phenyl]-ethylcarbamoyl}-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46),
- 35 (S)-3-[4-(2,6-Dichloro-benzyl)-phenyl]-2-{{(4R,5R)-5-isopropylcarbamoyl}-[1,3]dioxolane-4-carbonyl}-amino]- propionic acid (Compound No.47),

- (S)-2-[{(4R,5R)-5-tert-Butyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48),
- (S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-[{(4R,5R)-5-(3-methyl-butylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 49),
- 5 (S)-3-[4-(2,6,Dichloro-benzyloxy-phenyl]-2-{{(4R,5R)-5-[(R)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 50),
- (S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-{{(4R,5R)-5-[(S)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 51),
- 10 (S)-1-{{(4R,5R)-5-{(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl}-[1,3]dioxolane-4-carbonyl}-pyrrolidine-2-carboxylic acid benzyl ester(Compound No. 52),
- (S)-2-{{(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.53),
- 15 (S)-2-[(4R,5R)-{5-Benzyl-oxycarbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54),
- (S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(morpholine-4-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino-propionic acid (Compound No.55),
- (S)-2-[((4R,5R)-{5-allyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56),
- 20 1-{{(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl}-[1,3]dioxolane-4-carbonyl}-pyrrolidine-2-carboxylic acid (Compound No.57),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(tetrahydro-furan-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 58),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[2-(1H-indol-3-yl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 59),
- (S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(2-thiophen-2-yl-ethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 60),
- 30 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(pyridin-4-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No.61),
- (S)-3-[4-(2,6,-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2,3-dihydro-indole-1-carbonyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 62),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(5-methyl-[1,3,4]thiadiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No.63),
- 35 (S)-2{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-(4-hydroxyphenyl)-propionic acid (Compound No. 64),

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-(methyl-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.65),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{4R,5R)-5-[methyl-(1-methyl-piperidine-4-yl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 66),
- 5 (S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-{{(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 67),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2-methoxy-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 68),
- 10 (S)-2-{{(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69),
- (S)-2-{{(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(3,5-dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No.71),
- 15 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2,6-dichlorophenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 72),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-O-tolyl-carbamoyl}-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound no.73),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-dimethyl-carbamoyl}-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methyl-carbamoyl}-[1,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75),
- (S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methoxy-carbamoyl}-[1,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 76),
- 25 (4R,5R)-5-{{(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl)-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No.77),
- (S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 78),
- 30 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(R)-3-hydroxy-pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 80),
- 35 1-((4R,5R)-5-{{(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethylcarbamoyl}-[1,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81),

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(1-hydroxymethyl-propylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid
(Compound No. 82),
- 5 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-ethylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 83),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-prop-2-ynylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 84),
- 10 Trifluoroacetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2-morpholin-4-yl-ethylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 85),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 86),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 87),
- 15 (S)-2-{{(4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88),
- (S)-2-{{(4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90)
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2-isopropyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 91),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2,6-difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92),
- (S)-2-{{(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 93),
- 30 (S)-2-{{(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-[(pyridine-4-carbonyl)-amino]-phenyl]-propionic acid (Compound No. 94),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5S)-5-hydroxymethyl-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 95),
- (S)-2-{{(4R,5R)-5-Carbamoyl-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 96),
- 35 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-((R)-2-hydrox-1-phenyl-ethylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 97),

- (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98,)
- 5 (S)-2-{[(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 99),
- (S)-2-{[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100),
- (S)-2-{[(4R,5R)-5-Benzylloxymethyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101),
- 10 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-trifluoromethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 102),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropoxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 15 103),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 104),
- (S)-2-{[(4R,5R)-5-Cyclopentylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 105),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-hexylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 106),
- (S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,4-dimethyl-isoxazol-5-ylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]amino}-propionic acid (Compound No. 107),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyridin-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 108),
- {2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-1,2,3,4-tetrahydro-isoquinoline}-3-carboxylic acid (Compound No. 109),
- 2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(1H-indol-3-yl)-propionic acid (Compound No. 110),
- 30 (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 111),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 112),
- 35 (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113),

- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-cyclohexylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 114),
- 5 (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 115),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-heptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 116),
- 10 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 117),
- (4R,5R)-[1,3]Dioxolane-4,5-dicarboxylic acid-4-({(S)-1-carbamoyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl}-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118),
- 15 (S)-2-{[(4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119),
- (S)-2-[((4R,5R)-5-cycloheptylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulphanyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 121),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 122),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethylthiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 123),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(R)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 124),
- 30 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-oxo-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 125),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl]-methyl-amino}-propionic acid (Compound No. 126),
- 35 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(indan-5-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 127),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-phenethylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 128),
- (S)-2-({(4R,5R)-5-[(Benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129),

- (S)-2-{{(4R,5R)-5-Butylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 130),
- (S)-2-{{(4R,5R)-5-(4-Acetyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 131),
- 5 (S)-2-{{(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 132),
- (S)-2-{{(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133),
- 10 3-Benzo[1,3]dioxol-5-yl-3-{{(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 134),
- (S)-2-{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-(2-methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135),
- 15 (S)-2-{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-(4-fluoro-phenyl)-propionic acid (Compound No. 136),
- (S)-2-{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-(2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137),
- (S)-3-{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 138),
- 20 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-octylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 139),
- 3-[{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-3-(3,4-dimethoxy-benzyl)-amino]-propionic acid (Compound No. 140),
- 25 (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5S)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 141),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(3,5-dichloro-pyridin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 142),
- 30 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{{(4R,5R)-5-(2-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 143),
- (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{{(4R,5R)-5-[2-(1H-indol-3-yl)-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl)-amino}-propionic acid (Compound No. 144),
- 35 (S)-2-{{(4R,5R)-5-Cyclohexylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino}-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 145),

Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezoxy)-phenyl]-2-[((4R,5S)-5-pyrrolidin-1-ylmethyl-[1,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146),

(S)-2-[((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147),

5 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-((4R,5R)-5-[(thiophen-2-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 148),

(S)-3-[4-(2,6-Dichloro-benzylxy)-phenyl]-2-[((4R,5S)-2,2,5-trimethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 149),

10 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(thiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 150),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 151),

15 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 152),

(S)-2-{[(4R,5R)-5-Cyclopropylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 153), and

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 154).

20 78. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 together with pharmaceutically acceptable carrier, excipients or diluents.

79. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, 25 rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable excipient.


80. A method of preventing, inhibiting or suppressing inflammatory condition in an 30 animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1.

81. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma,



rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 79.

- 5 82. A method of preventing, inhibiting or suppressing inflammatory disease in an animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 78.



83. A method of preparing a compound of Formula XVI




- 10 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;




- condensing the compound of Formula III with a compound of Formula IV to yield a
15 compound of Formula V;



hydrolyzing the compound of Formula V to yield a compound of Formula VI;




condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);




5 reducing the compound of Formula VIII to yield a compound of Formula XIII

(when R_2 is);




reacting the compound of Formula XIII with a compound of Formula XIV to yield a compound of Formula XV; and


$X-C(=O)R_9$
Formula XIV





hydrolyzing the compound of Formula XIV to yield a compound of Formula XVI.





84. A method of preparing a compound of Formula XI



its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
 5 diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;




condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




10


hydrolyzing the compound of Formula V to yield a compound of Formula VI;




condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);




- 5 condensing the compound of Formula VIII with a compound of Formula IX to yield a compound of Formula X (when R_2 is p -CH₂-C₆H₄-OH);



hydrolyzing the compound of Formula X to yield a compound of Formula XI.





85. A method of preparing a compound of Formula XII





its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a


- 5 compound of Formula II to yield a compound of Formula III;




condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




- 10 hydrolyzing the compound of Formula V to yield a compound of Formula VI;




condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);



the compound of Formula VIII is hydrolyzed to yield a compound of Formula XII.




86. A method for preparing a compound of Formula XXI




5

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII:




10


hydrolyzing the compound of Formula XVIII to yield a compound of Formula XIX:




condensing the compound of Formula XIX with a compound of Formula IV to furnish a compound of Formula XX; and






- 5 hydrolyzing the compound of Formula XX to yield a compound of Formula XXI.




87. A method for preparing a compound of Formula XXI



- its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
 10 diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;




hydrolyzing the compound of Formula XVIII to yield a compound of Formula XXII; and




condensing the compound of Formula XXIII with a compound of Formula IV to yield a




5 compound of Formula XXI.





88. A method for preparing a compound of Formula XXIV




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
10 diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;




reacting the compound of Formula XVIII with a compound of Formula IX (when R₂ is p-hydroxy benzyl) to yield a compound of Formula XXIII; and




5 hydrolyzing the compound of Formula XXIII to yield a compound of Formula XXIV.




89. A method for preparation of compound of Formula XXVII




10 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




to yield a compound of Formula XXVI (wherein P₁ is ethyl, t-butyl, or benzyl); and



hydrolyzing the compound of Formula XXVI to furnish a compound of Formula XXVII.




5 90. A method for preparation of compound of Formula XXIII




Formula XXIII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




to yield a compound of Formula XXVI (wherein P₁ is ethyl, t-butyl, or benzyl); and reacting the compound of Formula XXVI with a compound of Formula R_m-hal to yield a compound of Formula XXVIII; and




5


hydrolyzing the compound of Formula XXVIII to yield a compound of Formula XXXIII.




91. A method for preparation of compound of Formula XXXIV




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV



- 5 to yield a compound of Formula XXVI (wherein P1 is ethyl, t-butyl, or benzyl); and reacting the compound of Formula XXVI with a compound of Formula Rm-hal to yield a compound of Formula XXIX; and




hydrolyzing the compound of Formula XXIX to yield a compound of Formula XXXIV.




10

92. A method for preparation of compound of Formula XXXII




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV




5


to yield a compound of Formula XXVI (wherein P_1 is ethyl, t-butyl, or benzyl); and reacting the compound of Formula XXVI with a compound of Formula L-hal to yield a compound of Formula XXX;




- 10 condensing the compound of Formula XXX with a compound of Formula IV (wherein OL is a leaving group selected from, mesyl or tosyl) to yield a compound of Formula XXXI; and




hydrolyzing the compound of Formula XXXI to yield a compound of Formula XXXII.




93. A method for the preparation of the compound of Formula XXXVIII





its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises hydrolyzing a compound of Formula XXXV to yield a compound of Formula XXXVI;






reacting the compound of Formula XXXVI with a compound of Formula VII to yield a compound of Formula XXXVII; and





- 5 hydrolyzing the compound of Formula XXXIII to yield a compound of Formula XXXVIII.

94. A method for the preparation of the compound of Formula XL



- its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, 10 diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula VI with a compound of Formula XXXIX



to yield a compound of Formula XL.

95. A compound of claim 1, wherein

R₁ is hydrogen;

5 R₂ is

R₃ is -OH;

R₄ is -C(=O)R_z;

R₅ is hydrogen;

R₆ is hydrogen; and


10 m is 0.

96. The compound of claim 95, wherein R_z is -NH-(CH₂)₀₋₃-aryl, -NH-(CH₂)₀₋₂-substituted aryl, -NH-(CH₂)₀₋₃-cycloalkyl, -NH-(CH₂)₀₋₃-heteroaryl, -NH-(CH₂)₀₋₃-heterocyclyl, -NH-(CH₂)₀₋₃-substituted cycloalkyl, -NH-(CH₂)₀₋₃-substituted heteroaryl, -NH-(CH₂)₀₋₃-substituted heterocyclyl, N-containing heterocyclyl, substituted N-containing heterocyclyl, NH-alkyl, NH-substituted alkyl and NH₂.

97. The compound of claim 95, wherein W is H, OH, NHCO-(CH₂)₀₋₃-aryl, NHCO-(CH₂)₀₋₃-substituted aryl, NHCO-(CH₂)₀₋₃-heteroaryl, NHCO-(CH₂)₀₋₃-substituted aryl, OCO-(CH₂)₀₋₃-aryl, OCO-(CH₂)₀₋₃-substituted aryl, OCO-(CH₂)₀₋₃-heterosryl, OCO-(CH₂)₀₋₃-substituted aryl, O-(CH₂)₀₋₃-heterocyclyl, -O-(CH₂)₀₋₃-substituted heterocyclyl, 20 NHCO-(CH₂)₀₋₃-heterocyclyl, NHCO-(CH₂)₀₋₃-substituted heterocyclyl, O-(CH₂)₀₋₃-alkynyl, O-(CH₂)₀₋₃-alkenyl, or halogen.

98. A compound of claim 1, wherein

R₁ is hydrogen;

R₂ is ;

R₃ is -OR_m;

5 R₅ is hydrogen;

R₆ is hydrogen; and

m is 0.

99. The compound of claim 98, wherein

R₄ is carboxyl, C₁₋₄ alkyl ester, hydroxyl methyl, CH₂OCH₂-C₆H₅, or

10 CH₂OCH₃.

100. The compound of claim 98, where R_m is hydrogen or C_{1-C₅} alkyl.

101. The compound of claim 98, herein W is H, OH, NHCO-(CH₂)₀₋₃-aryl, NHCO-(CH₂)₀₋₃-substituted aryl, NHCO-(CH₂)₀₋₃-heteroaryl, NHCO-(CH₂)₀₋₃-substituted aryl, OCO-(CH₂)₀₋₃-aryl, OCO-(CH₂)₀₋₃-substituted aryl, OCO-(CH₂)₀₋₃-heterosryl, OCO-

15 (CH₂)₀₋₃-substituted aryl, O-(CH₂)₀₋₃-heterocycl, -O-(CH₂)₀₋₃-substituted heterocycl, NHCO-(CH₂)₀₋₃-heterocycl, NHCO-(CH₂)₀₋₃-substituted heterocycl, O-(CH₂)₀₋₃-alkynyl, O-(CH₂)₀₋₃-alkenyl, or halogen.

102. A compound of claim 1, wherein

R₁ is hydrogen or C₁₋₅ alkyl;

20 R₂ is OH, or NH₂;

R₅ is hydrogen;

R₆ is hydrogen; and

m is 0.

103. The compound of claim 102, wherein

25 R₄ is CONH-aryl, CONH-substituted aryl, or (CH₂)₁₋₃-O-CH₃.